BR112012016128A8 - Agente terapêutico (y-39983) para disfunção endotelial da córnea - Google Patents

Agente terapêutico (y-39983) para disfunção endotelial da córnea

Info

Publication number
BR112012016128A8
BR112012016128A8 BR112012016128A BR112012016128A BR112012016128A8 BR 112012016128 A8 BR112012016128 A8 BR 112012016128A8 BR 112012016128 A BR112012016128 A BR 112012016128A BR 112012016128 A BR112012016128 A BR 112012016128A BR 112012016128 A8 BR112012016128 A8 BR 112012016128A8
Authority
BR
Brazil
Prior art keywords
corneal endothelial
endothelial cells
compound
therapeutic agent
corneal
Prior art date
Application number
BR112012016128A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012016128A2 (pt
Inventor
Takahashi Hiroaki
Sakamoto Yuji
Kida Tetsuo
Tarui Takeshi
Original Assignee
Senju Pharma Co
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co, Mitsubishi Tanabe Pharma Corp filed Critical Senju Pharma Co
Publication of BR112012016128A2 publication Critical patent/BR112012016128A2/pt
Publication of BR112012016128A8 publication Critical patent/BR112012016128A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112012016128A 2009-12-29 2010-12-28 Agente terapêutico (y-39983) para disfunção endotelial da córnea BR112012016128A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009299180 2009-12-29
PCT/JP2010/071424 WO2011080984A1 (en) 2009-12-29 2010-11-24 Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction
PCT/JP2010/073904 WO2011081221A1 (en) 2009-12-29 2010-12-28 Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction

Publications (2)

Publication Number Publication Date
BR112012016128A2 BR112012016128A2 (pt) 2016-05-31
BR112012016128A8 true BR112012016128A8 (pt) 2017-12-05

Family

ID=43598277

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012016128A BR112012016128A8 (pt) 2009-12-29 2010-12-28 Agente terapêutico (y-39983) para disfunção endotelial da córnea

Country Status (10)

Country Link
US (1) US20120288482A1 (https=)
EP (1) EP2519237A1 (https=)
JP (2) JP5750444B2 (https=)
KR (1) KR20120099147A (https=)
CN (1) CN102770136A (https=)
BR (1) BR112012016128A8 (https=)
CA (1) CA2785851A1 (https=)
MX (1) MX2012007671A (https=)
RU (1) RU2563141C2 (https=)
WO (2) WO2011080984A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2788472T (lt) * 2011-12-06 2019-04-10 Astellas Institute For Regenerative Medicine Kryptingos diferenciacijos būdas, skirtas ragenos endotelio ląstelių gamybai
BR112016011096A2 (pt) 2013-11-27 2017-09-19 Kyoto Prefectural Public Univ Corp Aplicação de laminina à cultura de célula endotelial da córnea
WO2015097920A1 (ja) * 2013-12-27 2015-07-02 京都府公立大学法人 角膜内皮細胞の細胞治療併用剤
JP6598381B2 (ja) * 2014-09-24 2019-10-30 興和株式会社 角膜厚調節剤
CN121891508A (zh) * 2014-10-31 2026-04-21 京都府公立大学法人 使用层粘连蛋白的新的角膜的治疗
EP3213761B1 (en) 2014-10-31 2021-05-19 Kyoto Prefectural Public University Corporation Novel treatment of retina using laminin
PL3416658T3 (pl) * 2016-02-15 2023-09-04 Kyoto Prefectural Public University Corporation Funkcjonalna ludzka komórka śródb‎łonka rogówki i jej zastosowanie

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1195372A1 (en) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
CN100411686C (zh) 2001-04-11 2008-08-20 千寿制药株式会社 视觉功能障碍改善剂
JP2004024852A (ja) 2002-04-30 2004-01-29 Amniotec:Kk 角膜内皮様シート、及びその作製方法
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
WO2005118582A1 (ja) * 2004-06-03 2005-12-15 Senju Pharmaceutical Co., Ltd. アミド化合物を含有する角膜知覚回復剤
JPWO2006057270A1 (ja) * 2004-11-26 2008-06-05 旭化成ファーマ株式会社 含窒素３環化合物
JP4766653B2 (ja) * 2005-01-28 2011-09-07 株式会社林原生物化学研究所 眼科用医薬組成物
US20090062295A1 (en) * 2005-03-10 2009-03-05 Mitsubishi Pharma Corporation Pharmaceutical Products
WO2007083685A1 (ja) * 2006-01-19 2007-07-26 Senju Pharmaceutical Co., Ltd. 生体内で細胞増殖可能な角膜内皮製剤
BRPI0714782A2 (pt) * 2006-07-31 2013-07-16 Senju Pharma Co preparaÇço lÍquida aquosa contendo composto de amida
KR20210070407A (ko) 2007-08-29 2021-06-14 센주 세이야꾸 가부시키가이샤 각막 내피 세포 접착 촉진제
JP5251632B2 (ja) 2008-05-13 2013-07-31 新日鐵住金株式会社 耐遅れ破壊特性に優れた高強度鋼材、高強度ボルト及びその製造方法
JP2010071424A (ja) 2008-09-19 2010-04-02 Toyota Motor Corp 変速機の制御装置

Also Published As

Publication number Publication date
KR20120099147A (ko) 2012-09-06
MX2012007671A (es) 2012-08-23
JP2013515676A (ja) 2013-05-09
RU2012132443A (ru) 2014-02-10
RU2563141C2 (ru) 2015-09-20
WO2011081221A1 (en) 2011-07-07
JP5750444B2 (ja) 2015-07-22
CA2785851A1 (en) 2011-07-07
JP2015155460A (ja) 2015-08-27
CN102770136A (zh) 2012-11-07
WO2011080984A1 (en) 2011-07-07
BR112012016128A2 (pt) 2016-05-31
EP2519237A1 (en) 2012-11-07
US20120288482A1 (en) 2012-11-15

Similar Documents

Publication Publication Date Title
BR112012016128A8 (pt) Agente terapêutico (y-39983) para disfunção endotelial da córnea
EP4512484A3 (en) Excipients for nicotine-containing therapeutic compositions
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
MX348245B (es) Tratamiento de la degeneracion del disco intervertebral mediante el uso de celulas humanas derivadas de tejido del cordon umbilical.
CL2007002228A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composiicon empacada; metodos para esterelizarlas; util para cicatrizar tejido donde la dermis se ha desgarrado.
NO20082477L (no) Krystallinske former av 1-benzoyl-4-[2-[4-metoksy-7-(3-metyl-1H-1,2,4-triazol-1-yl-1-[(fosfonooksy)metyl]-1H-pyrrolo[2,3-C]pyridin-3-yl]-1,2-dioksoetyl]-piperazin
WO2008056368A3 (en) Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
WO2009089110A3 (en) Methods for repair and regeneration of bone marrow
WO2008054544A3 (en) Method for delivery across the blood brain barrier
BRPI0608152A2 (pt) formulações para tratamento ocular
WO2012047587A3 (en) Mdm2 inhibitors for treatment of ocular conditions
CY1108794T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
MX2010010505A (es) Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf).
MX2010009395A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos.
EA201270629A1 (ru) Новые полиморфные формы метил(4,6-диамино-2-[1-(2-фторбензил)-1h-пиразоло[3,4-b]пиридин-3-ил]пиримидин-5-ил)карбамата
WO2011118954A3 (ko) 사람 하비갑개 유래 중간엽 기질세포로부터 연골, 골, 신경세포 또는 지방세포를 분화시키는 방법
JP2013515676A5 (https=)
BR112014009761B8 (pt) Composição de reticulação melhorada entregue por iontoforese, útil para o tratamento de ceratocone
CO6460763A2 (es) Métodos y formulaciones ectoparasiticidas
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
WO2008121422A3 (en) Implantable cell matrix composition for delivery of bioactive compounds
BR112013026644A2 (pt) método para a modulação da atividade de citocina
BRPI0716423A2 (pt) Terapêutica promotora de restauração de nervo espinhal contendo desacil grelina ou seus derivados como ingrediente ativo
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
AR074724A1 (es) Sal de citrato 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo (19.3.1.1(2,6).1(8,12) heptacosa-1-(25),2(26),3,5,8,10,12 (27),16,21,23-decaeno

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SENJU PHARMACEUTICAL CO., LTD (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30/10/2018.